TBIO Telesis Bio, Inc: Net earnings per share for the last four quarters

Telesis Bio, Inc. (TBIO) is scaling B2B deliveries of BioXp systems for mRNA synthesis, capturing a larger share of the pharmaceutical market. The annual growth trend of net income per share TTM reflects the dynamics of this process, with the latest value recorded as 27.60. Device manufacturing and logistics are outsourced to partners. Independence from macroeconomic factors and the demand for innovation transform the company into a resilient defensive asset.
TBIO (Telesis Bio Inc.): analytical breakdowns and indicator data

Telesis Bio, Inc. (TBIO) occupies a strategic niche in the DNA synthesis sector, protected by strict export laws. The annual change in EPS (TTM) measures the growth rate of net income per share over a rolling year. Investors utilize this metric to verify the actual profitability of the business, regardless of accounting manipulations. The steady growth of the curve confirms the effectiveness of the expansion into the laboratory market. The price action of the annual EPS (TTM) change serves as a quality filter for the asset.